Potential role in treatment of AD include reductions in inflammatory cytokines (Heneka et al., 2005[41]), oxidative stress (Nicolakakis et al., 2008[72]), Aβ deposits (Heneka et al., 2005[41]), glial activation (Nicolakakis et al., 2008[72]), tau phosphorylation (To et al., 2011[95]), and glucocorticoid signaling (Escribano et al., 2009[26]; Garcia-Bueno et al., 2005[31]). Here, MAPT is linked to Alzheimer disease.